|
GB532822A
(en)
|
1939-08-11 |
1941-01-31 |
John David Kendall |
Improvements in and relating to the production of ª‡-coumarilyl and ª‡-thionaphthenoyl-acetic acid esters
|
|
US4342691A
(en)
|
1980-04-28 |
1982-08-03 |
American Cyanamid Company |
ω-Heteroaroyl(propionyl or butyryl)-L-prolines
|
|
US4342690A
(en)
|
1980-04-28 |
1982-08-03 |
American Cyanamid Company |
ω-Heteroaroyl(propionyl or butyryl)-L-prolines
|
|
US4299769A
(en)
*
|
1980-04-28 |
1981-11-10 |
American Cyanamid Company |
ω-Heteroaroyl(propionyl or butyryl)-L-prolines
|
|
US4342689A
(en)
|
1980-04-28 |
1982-08-03 |
American Cyanamid Company |
ω-Heteroaroyl(propionyl or butyryl)-L-prolines
|
|
EP0146243A1
(en)
|
1983-10-31 |
1985-06-26 |
Merck Frosst Canada Inc. |
Lipoxygenase inhibitors
|
|
DE68924308T2
(de)
|
1988-07-11 |
1996-04-04 |
Akzo Nobel Nv |
Pyridazinon-Derivate.
|
|
ATE188379T1
(de)
|
1992-10-14 |
2000-01-15 |
Merck & Co Inc |
Fibrinogenrezeptor-antagonisten
|
|
US5569655A
(en)
|
1993-09-14 |
1996-10-29 |
Sterling Winthrop Inc. |
Substituted heterocyclylisoquinolinium salts and compositions and method of use thereof
|
|
CA2333771A1
(en)
|
1998-06-03 |
1999-12-09 |
Mark W. Embrey |
Hiv integrase inhibitors
|
|
US6262055B1
(en)
|
1998-06-03 |
2001-07-17 |
Merck & Co., Inc. |
HIV integrase inhibitors
|
|
PE20010306A1
(es)
|
1999-07-02 |
2001-03-29 |
Agouron Pharma |
Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
|
|
GB0018891D0
(en)
|
2000-08-01 |
2000-09-20 |
Novartis Ag |
Organic compounds
|
|
WO2001070675A2
(en)
|
2000-03-24 |
2001-09-27 |
Methylgene, Inc. |
Inhibitors of histone deacetylase
|
|
US6448288B1
(en)
|
2000-05-17 |
2002-09-10 |
University Of Massachusetts |
Cannabinoid drugs
|
|
JP2004531238A
(ja)
|
2001-02-26 |
2004-10-14 |
ファーマ パシフィック プロプライエタリー リミテッド |
インターフェロン−アルファ誘導遺伝子
|
|
EP1537878B1
(en)
|
2002-07-03 |
2010-09-22 |
Ono Pharmaceutical Co., Ltd. |
Immunopotentiating compositions
|
|
WO2004056875A1
(en)
|
2002-12-23 |
2004-07-08 |
Wyeth |
Antibodies against pd-1 and uses therefor
|
|
EP1591527B1
(en)
|
2003-01-23 |
2015-08-26 |
Ono Pharmaceutical Co., Ltd. |
Substance specific to human pd-1
|
|
US7576122B2
(en)
|
2003-09-02 |
2009-08-18 |
Merck & Co. Inc. |
Ophthalmic compositions for treating ocular hypertension
|
|
EP1740192B1
(en)
|
2004-03-15 |
2012-06-13 |
David K. R. Karaolis |
Cyclic dinucleotide for stimulating the immune of inflammatory response
|
|
EP2418278A3
(en)
|
2005-05-09 |
2012-07-04 |
Ono Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
|
|
KR101607288B1
(ko)
|
2005-07-01 |
2016-04-05 |
이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. |
예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
|
|
AU2006304897B2
(en)
|
2005-10-18 |
2012-07-12 |
Janssen Pharmaceutica N.V. |
Method of inhibiting FLT3 kinase
|
|
EP1782826A1
(en)
|
2005-11-08 |
2007-05-09 |
GBF Gesellschaft für Biotechnologische Forschung mbH |
PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions
|
|
CA2947292C
(en)
|
2006-12-27 |
2019-07-23 |
Emory University |
Compositions and methods for the treatment of infections and tumors
|
|
EP2535354B1
(en)
|
2007-06-18 |
2017-01-11 |
Merck Sharp & Dohme B.V. |
Antibodies to human programmed death receptor pd-1
|
|
US8168757B2
(en)
|
2008-03-12 |
2012-05-01 |
Merck Sharp & Dohme Corp. |
PD-1 binding proteins
|
|
US20110159023A1
(en)
|
2008-08-25 |
2011-06-30 |
Solomon Langermann |
Pd-1 antagonists and methods for treating infectious disease
|
|
HUE030807T2
(en)
|
2008-09-26 |
2017-05-29 |
Dana Farber Cancer Inst Inc |
Human anti-PD-1, anti-PD-L1 and anti-PD-L2 antibodies and their applications
|
|
WO2010047774A2
(en)
|
2008-10-20 |
2010-04-29 |
The Texas A & M University System |
Inhibitors of mycobacterium tuberculosis malate synthase, methods of marking and uses thereof
|
|
TWI729512B
(zh)
|
2008-12-09 |
2021-06-01 |
美商建南德克公司 |
抗pd-l1抗體及其於增進t細胞功能之用途
|
|
EP2504028A4
(en)
|
2009-11-24 |
2014-04-09 |
Amplimmune Inc |
SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
|
|
WO2012068702A1
(zh)
|
2010-11-23 |
2012-05-31 |
中国医学科学院医药生物技术研究所 |
苯并五元不饱和杂环类化合物及其制备方法
|
|
JP5887947B2
(ja)
|
2011-03-28 |
2016-03-16 |
ソニー株式会社 |
透明導電膜、ヒータ、タッチパネル、太陽電池、有機ｅｌ装置、液晶装置および電子ペーパ
|
|
WO2012142075A1
(en)
|
2011-04-13 |
2012-10-18 |
Merck Sharp & Dohme Corp. |
2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
|
BR122022000334B1
(pt)
|
2011-08-01 |
2023-03-21 |
Genentech, Inc |
Composição farmacêutica compreendendo um antagonista de ligação ao eixo pd-1 e um inibidor de mek
|
|
WO2013185052A1
(en)
|
2012-06-08 |
2013-12-12 |
Aduro Biotech |
Compostions and methods for cancer immunotherapy
|
|
BR112015013440B1
(pt)
|
2012-12-13 |
2020-12-08 |
Aduro Biotech, Inc |
composições compreendendo dinucleotídeos de purina cíclicos com estereoquímicas
|
|
WO2014099824A1
(en)
|
2012-12-19 |
2014-06-26 |
Board Of Regents, The University Of Texas System |
Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
|
|
WO2014099941A1
(en)
|
2012-12-19 |
2014-06-26 |
Idenix Pharmaceuticals, Inc. |
4'-fluoro nucleosides for the treatment of hcv
|
|
WO2014139388A1
(en)
|
2013-03-14 |
2014-09-18 |
Merck Sharp & Dohme Corp. |
Novel indole derivatives useful as anti-diabetic agents
|
|
CA2908154C
(en)
|
2013-04-29 |
2023-11-28 |
Memorial Sloan Kettering Cancer Center |
Compositions and methods for altering second messenger signaling
|
|
JP2016518140A
(ja)
|
2013-05-03 |
2016-06-23 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
Ｉ型インターフェロンの環状ジヌクレオチド誘導法
|
|
SI2996473T1
(sl)
|
2013-05-18 |
2019-12-31 |
Aduro Biotech, Inc. |
Sestavki in postopki za aktiviranje signaliziranja, odvisnega od "stimulator interferonskih genov"
|
|
US9549944B2
(en)
|
2013-05-18 |
2017-01-24 |
Aduro Biotech, Inc. |
Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
|
|
EP2996472B1
(en)
|
2013-05-18 |
2019-03-27 |
Aduro Biotech, Inc. |
Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling
|
|
EP3027227A4
(en)
|
2013-07-31 |
2018-05-23 |
Memorial Sloan Kettering Cancer Center |
Sting crystals and modulators
|
|
WO2015077354A1
(en)
|
2013-11-19 |
2015-05-28 |
The University Of Chicago |
Use of sting agonist as cancer treatment
|
|
WO2015074145A1
(en)
|
2013-11-22 |
2015-05-28 |
Brock University |
Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants
|
|
US9315523B2
(en)
|
2013-12-06 |
2016-04-19 |
Rutgers, The State University Of New Jersey |
Cyclic dinucleosides
|
|
WO2015143712A1
(en)
|
2014-03-28 |
2015-10-01 |
Merck Sharp & Dohme Corp. |
4'-substituted nucleoside reverse transcriptase inhibitors
|
|
WO2015161137A1
(en)
|
2014-04-16 |
2015-10-22 |
Idenix Pharmaceuticals, Inc. |
3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
|
|
CN103908468B
(zh)
|
2014-04-21 |
2017-02-08 |
上海捌加壹医药科技有限公司 |
环二核苷酸cGAMP在制备抗肿瘤药物中的应用
|
|
ES2692226T3
(es)
|
2014-06-04 |
2018-11-30 |
Glaxosmithkline Intellectual Property Development Limited |
Dinucleótidos cíclicos como moduladores de STING
|
|
WO2015189117A1
(de)
|
2014-06-12 |
2015-12-17 |
Bayer Pharma Aktiengesellschaft |
Heterobicyclisch substituierte 4-oxobutansäure-derivate und ihre verwendung
|
|
CA2955676A1
(en)
*
|
2014-08-25 |
2016-03-03 |
Pfizer Inc. |
Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
|
|
US10011630B2
(en)
|
2014-12-16 |
2018-07-03 |
Invivogen |
Cyclic dinucleotides for cytokine induction
|
|
US20170340658A1
(en)
|
2014-12-16 |
2017-11-30 |
Invivogen |
Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment
|
|
US20180344758A1
(en)
|
2014-12-17 |
2018-12-06 |
Lipogen Llc |
Method of Treating Cancer with cGAMP or cGAsMP
|
|
GB201501462D0
(en)
|
2015-01-29 |
2015-03-18 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
JO3746B1
(ar)
|
2015-03-10 |
2021-01-31 |
Aduro Biotech Inc |
تركيبات وطرق لتنشيط الإشارات المعتمدة على "منبه أو تحفيز جين انترفيرون"
|
|
WO2017011622A1
(en)
|
2015-07-14 |
2017-01-19 |
Spring Bank Pharmaceuticals, Inc. |
Compounds and compositions that induce rig-i-and other pattern recongnition receptors
|
|
CA3030582A1
(en)
|
2015-07-22 |
2017-01-26 |
The Royal Institution For The Advancement Of Learning/Mcgill University |
Compounds and uses thereof in the treatment of cancers and other medical conditions
|
|
US20180222982A1
(en)
|
2015-07-29 |
2018-08-09 |
Novartis Ag |
Combination therapies comprising antibody molecules to pd-1
|
|
CA2995365C
(en)
|
2015-08-13 |
2021-10-12 |
Merck Sharp & Dohme Corp. |
Cyclic di-nucleotide compounds as sting agonists
|
|
US9809597B2
(en)
|
2015-08-20 |
2017-11-07 |
The Board Of Trustees Of The Leland Stanford Junior University |
Ganciclovir derivatives for modulating innate and adaptive immunity and for use in immunotherapy
|
|
AU2016343993A1
(en)
|
2015-10-28 |
2018-05-10 |
Aduro Biotech, Inc. |
Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
|
|
US20170146519A1
(en)
|
2015-11-20 |
2017-05-25 |
Oregon Health & Science University |
Sting agonists and methods of selecting sting agonists
|
|
CR20180286A
(es)
*
|
2015-12-03 |
2018-07-16 |
Glaxosmithkline Ip Dev Ltd |
Dinucleotidos de purina cíclicos como moduladores de sting
|
|
CA3007311A1
(en)
|
2015-12-07 |
2017-06-15 |
Opi Vi - Ip Holdco Llc |
Compositions of antibody construct-agonist conjugates and methods of use thereof
|
|
JP2019503349A
(ja)
*
|
2015-12-17 |
2019-02-07 |
ノバルティス アーゲー |
Ｐｄ−１に対する抗体分子およびその使用
|
|
CN109451740B
(zh)
|
2016-01-11 |
2022-09-02 |
先天肿瘤免疫公司 |
用于治疗与sting活性相关的病症诸如癌症的环状二核苷酸
|
|
US10723756B2
(en)
|
2016-01-11 |
2020-07-28 |
Innate Tumor Immunity Inc. |
Cyclic dinucleotides for treating conditions associated with STING activity such as cancer
|
|
MX390014B
(es)
|
2016-03-18 |
2025-03-20 |
Immune Sensor Llc |
Compuestos de dinucleótidos cíclicos y métodos de uso.
|
|
SI3440076T1
(sl)
|
2016-04-07 |
2022-09-30 |
Glaxosmithkline Intellectual Property Development Limited |
Heterociklični amidi uporabni kot proteinski modulatorji
|
|
BR112018070602A2
(pt)
|
2016-04-07 |
2019-02-05 |
Glaxosmithkline Ip Dev Ltd |
composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio
|
|
MA45244A
(fr)
|
2016-06-13 |
2019-04-17 |
Cancer Research Tech Ltd |
Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1
|
|
EP3507367A4
(en)
|
2016-07-05 |
2020-03-25 |
Aduro BioTech, Inc. |
CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
|
|
CR20190168A
(es)
|
2016-10-04 |
2019-05-17 |
Merck Sharp & Dohme |
Compuestos de benzo[b]tiofeno como agonistas de sting
|